Clinical Trials Logo

Filter by:
NCT ID: NCT06356506 Not yet recruiting - Clinical trials for Autoimmune Hepatitis

A Study on Factors of Biochemical Response in Autoimmune Hepatitis

Start date: May 1, 2024
Phase:
Study type: Observational

The goal of this observational study is to clarify the clinical characteristics of autoimmune hepatitis (AIH) in China. The main questions it aims to answer are: Human leukocyte antigen (HLA) gene susceptibility in Chinese AIH patients prognostic factors associated with AIH Participants will provide liver tests results and details of treatment during follow-up.

NCT ID: NCT06356441 Not yet recruiting - Clinical trials for Artificial Intelligence Supported Image Reviewing

Artificial Intelligence-supported Reading Versus Standard Double Reading for the Interpretation of Magnetic Resonance Imaging in the Detection of Local Recurrence for Nasopharyngeal Carcinoma: a Randomised Controlled Multicenter Study

Start date: April 2024
Phase:
Study type: Observational

The aim of this randomized controlled study is to investigate whether the previously developed artificial intelligence model can triage post-radiotherapy magnetic resonance images of patients with nasopharyngeal carcinoma and assist radiologists in their interpretation.

NCT ID: NCT06355609 Not yet recruiting - Clinical trials for Non-small Cell Lung Cancer

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

WUKONG-32-RW
Start date: April 30, 2024
Phase: Phase 2
Study type: Interventional

This is a phase II, open-label, single-arm, single-center clinical study to evaluate the preliminary efficacy of sunvozertinib in combination with anlotinib in patients with EGFR-sensitive mutations and co-mutations in locally advanced or metastatic treatment-naive non-small cell lung cancer.

NCT ID: NCT06354114 Not yet recruiting - Clinical trials for Advanced Breast Cancer

A Study to Evaluate the Efficacy and Safety in Subjects With Advanced Breast Cancer Treated With SYHX2011

Start date: April 2024
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the efficacy and safety in subjects with advanced breast cancer treated with SYHX2011

NCT ID: NCT06353646 Not yet recruiting - Pancreatic Cancer Clinical Trials

XH001 Combination With Ipilimumab and Chemotherapy for Patients With Resected Pancreatic Cancer

Start date: April 2024
Phase: N/A
Study type: Interventional

This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with ipilimumab and chemotherapy in pancreatic cancer patients following surgical resection.

NCT ID: NCT06353334 Not yet recruiting - Cardiac Arrest Clinical Trials

Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA Trial)

Start date: April 30, 2024
Phase: Phase 4
Study type: Interventional

Butylphthalide (NBP) is a neuroprotective medication capable of ameliorating neurological dysfunction induced by ischemia, hypoxia, and reperfusion injury in the brain. However, evidence regarding the improvement of neurological function prognosis in patients with return of spontaneous circulation (ROSC) after cardiac arrest (CA) by NBP is limited. This study aims to evaluate the safety and efficacy of NBP treatment in improving the neurological function prognosis of patients with ROSC after CA.The study will be a single-center, randomized, double-blind, placebo-controlled trial. The sample size is estimated to be 100 patients. Eligible patients will be randomly allocated in a 1:1 ratio to receive either NBP or placebo treatment daily for a duration of 14 days. The initial administration of NBP or placebo treatment will commence within 6 hours after ROSC following CA. The primary outcome is the proportion of patients with Cerebral Performance Category (CPC) scores of 1-2 at 90 days after randomization in each group. The primary safety outcome is the percentage of severe adverse events occurring during the 14-day treatment period. This trial will determine the efficacy of NBP in providing neuroprotective effects for patients with ROSC after CA.

NCT ID: NCT06352320 Not yet recruiting - Cardiomyopathies Clinical Trials

Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH)

Start date: December 31, 2024
Phase:
Study type: Observational

This study will include patients with different types of cardiomyopathy from multiple centers were prospectively enrolled in a retrospective study to establish a natural population cohort of cardiomyopathy patients. By collecting clinical data and biological samples from surgical patients, we will construct a prognostic system for cardiomyopathy, optimize risk stratification, explore new strategies for the early prevention and treatment of cardiomyopathy, and improve the efficiency of clinical cardiomyopathy patients' diagnosis and treatment.

NCT ID: NCT06352307 Not yet recruiting - Clinical trials for Arrhythmogenic Cardiomyopathy

Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy

STARTER
Start date: December 31, 2024
Phase:
Study type: Observational

This study will include patients diagnosed with Arrhythmogenic cardiomyopathy (ACM) in the First Affiliated Hospital of Xi 'an Jiaotong University and other centers, and collect clinical data and biological samples of patients with different ACM phenotypes. Through the establishment of disease cohort and long-term follow-up, to explore the disease characteristics, development law, clinical characteristics, natural course of disease and long-term prognosis of ACM.

NCT ID: NCT06352190 Not yet recruiting - Healthy Subjects Clinical Trials

A Study to Evaluate the Mass Balance of [14C] SY-5007 in Healthy Adult Male Subjects in China

Start date: May 1, 2024
Phase: Phase 1
Study type: Interventional

This is a single-center, open-label, non-randomized, single dose study in healthy male subjects designed to assess mass balance recovery, metabolite profile and metabolite identification of radio-labeled SY-5007 administered orally.

NCT ID: NCT06352034 Not yet recruiting - Empathy Clinical Trials

Empathy Training for Psychology Students Trainees

Start date: May 20, 2024
Phase: N/A
Study type: Interventional

This study aims to examine the effectiveness of empathy training for psychology student trainees who plan to become mental health practitioners. The training consists of five sessions of psychoeducation, three-role group exercises, and Q&A. Empathy assessment will be based on self-reported, listener-reported, and observer-reported measurements.